{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T20:25:53Z","timestamp":1783628753706,"version":"3.55.0"},"reference-count":13,"publisher":"Japanese Society of Internal Medicine","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,9,15]]},"DOI":"10.2169\/internalmedicine.5377-20","type":"journal-article","created":{"date-parts":[[2020,7,27]],"date-time":"2020-07-27T22:06:54Z","timestamp":1595887614000},"page":"2327-2329","source":"Crossref","is-referenced-by-count":14,"title":["Acute Gouty Arthritis During Favipiravir Treatment for Coronavirus Disease 2019"],"prefix":"10.2169","volume":"59","author":[{"given":"Ryota","family":"Hase","sequence":"first","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Japan"},{"name":"Department of Infectious Diseases, Kameda Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rika","family":"Kurata","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Japanese Red Cross Narita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Ishida","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Japan"},{"name":"Department of Infectious Diseases, Kameda Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kurita","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiri","family":"Muranaka","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Japan"},{"name":"Department of Infectious Diseases, Kameda Medical Center, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Mito","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Japanese Red Cross Narita Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res 100: 446-454, 2013.","DOI":"10.1016\/j.antiviral.2013.09.015"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Furuta Y, Komeno T, Nakamura T. Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase. Proc Jpn Acad Ser B Phys Biol Sci 93: 449-463, 2017.","DOI":"10.2183\/pjab.93.027"},{"key":"#cr-split#-3.1","unstructured":"3. Edagawa S, Kobayashi F, Kodama F, et al. Report of 15 cases of Covid-19 including 3 cases requiring mechanical ventilation. Transfer 10:13, 2020 [updated 2020 Mar 19"},{"key":"#cr-split#-3.2","unstructured":"cited 2020 May 7]. Available from: http:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_casereport_en_200402.pdf"},{"key":"4","unstructured":"4. Khambholja K, Asudani D. Potential repurposing of Favipiravir in COVID-19 outbreak based on current evidence. Travel Med Infect Dis Forthcoming."},{"key":"5","unstructured":"5. Avigan (favipiravir) [prescribing information]. Toyama Chemical Co. Ltd., Tokyo, Japan, 2014."},{"key":"#cr-split#-6.1","unstructured":"6. Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Report on the Deliberation Results [Internet]. [updated 2014 Mar 4"},{"key":"#cr-split#-6.2","unstructured":"cited 2020 May 7]. Available from: https:\/\/www.pmda.go.jp\/files\/000210319.pdf"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hayden F, Shindo N. Influenza virus polymerase inhibitors in clinical development. Curr Opin Infect Dis 32: 176-186, 2019.","DOI":"10.1097\/QCO.0000000000000532"},{"key":"#cr-split#-8.1","unstructured":"8. The Japanese Association for Infectious Diseases. Interim guidance of antiviral drugs for COVID-19 Ver1. 2020 [Internet]. [updated 2020 Feb 26"},{"key":"#cr-split#-8.2","unstructured":"cited 2020 Mar 13]. Available from: http:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_antiviral_drug_200227.pdf (in Japanese)"},{"key":"9","unstructured":"9. Cai Q, Yang M, Liu D, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering Forthcoming."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Janssens HJ, Fransen J, Van de Lisdonk EH, van Riel PL, van Weel C, Janssen M. A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. Arch Intern Med 170: 1120-1126, 2010.","DOI":"10.1001\/archinternmed.2010.196"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_5377-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,19]],"date-time":"2020-09-19T03:44:49Z","timestamp":1600487089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/18\/59_5377-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,15]]},"references-count":13,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5377-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,15]]}}}